200 related articles for article (PubMed ID: 8558202)
1. CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial.
Fridrik MA; Hausmaninger H; Linkesch W; Stöger M; Sill H; Neubauer M; Seewann HL; Klocker J; Haidinger R; Schiller L; Pont J; Raudaschl G; Falk M; Radaszkiewicz T
J Clin Oncol; 1996 Jan; 14(1):227-32. PubMed ID: 8558202
[TBL] [Abstract][Full Text] [Related]
2. Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor Therapy.
Fridrik MA; Greil R; Hausmaninger H; Krieger O; Oppitz P; Stöger M; Klocker J; Neubauer M; Helm W; Pont J; Fazeny B; Hudec M; Simonitsch I; Radaszkiewicz T
Ann Hematol; 1997 Oct; 75(4):135-40. PubMed ID: 9402845
[TBL] [Abstract][Full Text] [Related]
3. Toxicity and preliminary results with a new eight-drug regimen (CEOP-IMVP-DEXA) in the treatment of aggressive lymphomas.
Fridrik MA; Hausmaninger H; Michlmayr G; Haidinger R; Seewann HL; Lehnert M
Hematol Oncol; 1991; 9(4-5):209-15. PubMed ID: 1743623
[TBL] [Abstract][Full Text] [Related]
4. CEOP-B alternated with VIMB in intermediate-grade and high-grade non-Hodgkin's lymphoma: a pilot study.
De Lena M; Ditonno P; Lorusso V; Brandi M; Timurian A; Marzullo F; Ventrella V; Pellecchia A
J Clin Oncol; 1995 Apr; 13(4):953-60. PubMed ID: 7535844
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy in patients with acquired immunodeficiency virus syndrome associated with non-Hodgkin's lymphoma.
Fridrik MA; Geit M; Wahl G; Ehrengruber A; Simma R; Höpfel I; Bettelheim P; Leisch F
Wien Klin Wochenschr; 1998 Jan; 110(1):15-9. PubMed ID: 9499473
[TBL] [Abstract][Full Text] [Related]
6. Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphoma.
Fridrik MA; Hausmaninger H; Lang A; Drach J; Krieger O; Geissler D; Michlmayr G; Ulsperger E; Chott A; Oberaigner W; Greil R
Ann Hematol; 2010 Mar; 89(3):273-82. PubMed ID: 19693500
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
Federico M; Clò V; Brugiatelli M; Carotenuto M; Gobbi PG; Vallisa D; Lombardo M; Avanzini P; Di Renzo N; Dini D; Baldini L; Silingardi V
Haematologica; 1998 Sep; 83(9):800-11. PubMed ID: 9825577
[TBL] [Abstract][Full Text] [Related]
8. A cooperative study of epirubicin with cyclophosphamide, vincristine and prednisone (CEOP) in non-Hodgkin's lymphoma.
Lambertenghi Deliliers G; Butti C; Baldini L; Ceriani A; Lombardi F; Luoni M; Montalbetti L; Pavia G; Pinotti G; Pogliani E
Haematologica; 1995; 80(4):318-24. PubMed ID: 7590500
[TBL] [Abstract][Full Text] [Related]
9. [Risk-adapted therapy of highly malignant non-Hodgkin's lymphomas with COP-BLAM/IMVP-16: a prospective multicenter study].
Gerhartz HH; Wilmanns W; Brittinger G; Engelhard M; Heinz R; Huhn D; Meusers P; Siegert W; Stacher A; Thiel E
Onkologie; 1989 Feb; 12(1):22-6. PubMed ID: 2470000
[TBL] [Abstract][Full Text] [Related]
10. Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP.
Economopoulos T; Dimopoulos MA; Mellou S; Pavlidis N; Samantas E; Nicolaides C; Tsatalas C; Papadopoulos A; Papageogriou E; Papasavvas P; Fountzilas G
Eur J Haematol; 2002 Mar; 68(3):135-43. PubMed ID: 12068793
[TBL] [Abstract][Full Text] [Related]
11. Long-term results of dose density therapy in patients with aggressive lymphoma.
Fridrik MA; Hausmaninger H; Linkesch W; Greil R; Krieger O; Baldinger C; Klocker J; Pont J; Oberaigner W
Ann Hematol; 2005 Apr; 84(4):217-22. PubMed ID: 15538568
[TBL] [Abstract][Full Text] [Related]
12. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
13. A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy.
Sawada M; Tsurumi H; Yamada T; Hara T; Fukuno K; Goto H; Shimizu M; Kasahara S; Yoshikawa T; Kanemura N; Oyama M; Takami T; Moriwaki H
Eur J Haematol; 2002 Jun; 68(6):354-61. PubMed ID: 12225393
[TBL] [Abstract][Full Text] [Related]
14. Prospective multicenter trial for the response-adapted treatment of high-grade malignant non-Hodgkin's lymphomas: updated results of the COP-BLAM/IMVP-16 protocol with randomized adjuvant radiotherapy.
Engelhard M; Meusers P; Brittinger G; Brack N; Dornoff W; Enne W; Gassmann W; Gerhartz H; Hallek M; Heise J
Ann Oncol; 1991 Feb; 2 Suppl 2():177-80. PubMed ID: 1710919
[TBL] [Abstract][Full Text] [Related]
15. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
[TBL] [Abstract][Full Text] [Related]
16. Prospective randomized study comparing MEMID with a chop-like regimen in elderly patients with aggressive non-Hodgkin's lymphoma.
Chamorey E; Gressin R; Peyrade F; Rossi JF; Lepeu G; Foussard C; Harrousseau JL; Fabbro M; Richard B; Delwail V; Maisonneuve H; Vilque JP; Thyss A
Oncology; 2005; 69(1):19-26. PubMed ID: 16088231
[TBL] [Abstract][Full Text] [Related]
17. CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: A randomised multicenter study of Southern Italy Cooperative Group.
Lorusso V; Palmieri G; Bianco AR; Abate G; Catalano G; De Vita F; Dammacco F; Lauta VM; Lucarelli G; Polimeno G; Mantovani G; D'Aprile M; Marzullo F; De Lena M
Int J Oncol; 2000 Jan; 16(1):149-54. PubMed ID: 10601560
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP.
Dincol D; Buyukcelik A; Dogan M; Akbulut H; Samur M; Demirkazik A; Senler FC; Onur H; Icli F
Med Oncol; 2010 Sep; 27(3):942-5. PubMed ID: 19787462
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of cyclophosphamide,epirubicin, vincristine, prednisone, and etoposide (CEOP-E) for aggressive non-Hodgkin 's lymphoma.
Kim JG; Sohn SK; Kim DH; Baek JH; Park TI; Lee KB
J Korean Med Sci; 2004 Dec; 19(6):820-5. PubMed ID: 15608392
[TBL] [Abstract][Full Text] [Related]
20. Treatment of aggressive non-Hodgkin's lymphoma with dose-intensified epirubicin in combination of cyclophosphamide, vincristine, and prednisone (CEOP-100): a phase II study.
Basaran M; Bavbek ES; Sakar B; Eralp Y; Alici S; Tas F; Yaman F; Dogan O O; Camlica H; Onat H
Am J Clin Oncol; 2001 Dec; 24(6):570-5. PubMed ID: 11801756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
